Enliven Therapeutics (ELVN) Live Share Price, Invest From India

Enliven Therapeutics Stock Performance

as on September 18, 2026 at 1:12 am IST

Day's Low
Day's High
$49.32
Day's Price Range
$50.55
$50.17
1.69%
Downside
0.76%
Upside
52 Week's Low
52 Week's High
$14.79
52-Week Price Range
$62.32
$50.17
70.53%
Downside
24.22%
Upside

Enliven Therapeutics share price movements today

Previous Close: $49.12
Open: $49.79
Volume: 225.1K
Market Cap: $3.9B
Day's Low - High: $49.32 - $50.55
52 Week Low - High: $14.79 - $62.32

Enliven Therapeutics Historical Returns

1 Month Return: -17.49 %
3 Month Return: + 9.5 %
1 Year Return: + 158.25 %
3 Year Return: + 205.09 %
5 Year Return: 0 %

Enliven Therapeutics Stock Fundamentals & Key Indicators

Check Enliven Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$3.9B

EPS (TTM)

-1.64

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-32.54

Industry PE ratio

-14.99

PEG Ratio

-1.6382138621314437

EBITDA

-105.8M

Revenue (TTM)

Profit Margin

0.00%

Return On Equity TTM

-18.55%

Enliven Therapeutics Stock Valuation

Track how Enliven Therapeutics P/E has moved over time to understand its valuation trends.

Enliven Therapeutics in the last 5 years

Overview
Trends

Lowest (-11.90x)

December 31, 2024

Industry (-14.99x)

December 31, 2025

Today (-8.42x)

December 31, 2025

Highest (-2.71x)

December 31, 2022

LowHigh

Today’s Price to Earnings Ratio: -8.42x

Enliven Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Enliven Therapeutics with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %	Dividend Yield %
Enliven Therapeutics	BUY	$3.9B	NA	-32.54	0.00%	0.00%
Revolution Medicines	BUY	$43.9B	527.35%	NA	0.00%	0.00%
Vertex Pharmaceuticals	BUY	$130.4B	172.58%	29.71	86.04%	0.00%
Moderna	BUY	$57.4B	-66.14%	-18.02	-12.57%	0.00%
Regeneron	BUY	$81.7B	18.83%	18.48	84.86%	0.48%

Stock Returns calculator for Enliven Therapeutics Stock including INR - Dollar returns

The Enliven Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Enliven Therapeutics investment value today

Current value as on today

₹2,87,928

Returns

₹1,87,928

(+187.93%)

Returns from Enliven Therapeutics Stock

₹1,63,775 (+163.77%)

Dollar Impact

₹24,153 (+24.15%)

Analyst Recommendation on Enliven Therapeutics Stock

Based on 12 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 12 analysts, 100% of analysts recommend a 'BUY' rating for Enliven Therapeutics. Average target price of $73.9

Enliven Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Enliven Therapeutics.

What analysts predicted

32.11%UPSIDE

Target Price

$73.9

Current Price

$50.17

Analyzed by

12 Analysts

Target

$73.90

Enliven Therapeutics target price $73.9, a slight upside of 32.11% compared to current price of $50.17. According to 12 analysts rating.

Indian Investors' Interest in Enliven Therapeutics Stock

Search interest for Enliven Therapeutics Stock has decreased by -34% in the last 30 days, reflecting a downward trend in search activity.

Time period: August 18, 2026 to September 17, 2026

Change:-34% versus previous 30 day period

Enliven Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Total Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	0	0	-
Operating Income	-25	-24	-27	-26	-31	-28	-25	-34	-27	-37
EBITDA	-22	-19	-23	-23	-28	-25	-20	-29	-23	-32
Interest Expense	-	-	-	-	-	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0	0	-
Income Before Tax	-22	-19	-23	-23	-28	-25	-20	-29	-23	-32
Income Tax Expense	-	0	-	-	-	-	-	-	-	-
Net Income	-22	-19	-23	-23	-28	-25	-20	-29	-23	-32
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Enliven Therapeutics Annual Profit & Loss

All numbers in Millions USD

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	0	-	-	-	-	-	0
Operating Income	-8	-10	-24	-9	-24	-38	-83	-104	-119
EBITDA	0	-11	-23	-9	-24	-37	-71	-88	-103
Interest Expense	-	-	-	-	-	-	-	-	-
Depreciation	-	-	0	0	0	0	0	0	0
Income Before Tax	0	-11	-23	-18	-24	-37	-71	-88	-103
Income Tax Expense	0	-	-	-	-	-	-	0	-
Net Income	-	-11	-23	-18	-24	-37	-71	-89	-103
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Enliven Therapeutics Quarterly Cash Flow

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Net Income	-22	-19	-23	-23	-28	-25	-20	-29	-23	-32
Operating Cash Flow	-23	-20	-12	-17	-24	-17	-13	-15	-19	-18
Investing Cash Flow	-17	-33	14	0	1	-183	-4	12	42	-441
Financing Cash Flow	90	1	1	39	0	218	0	0	10	463
Change in Cash	49	-52	3	23	-22	17	-17	-2	33	3

Enliven Therapeutics Annual Cash Flow

All numbers in Millions USD

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Net Income	-	-11	-23	-18	-24	-37	-71	-89	-103
Operating Cash Flow	-8	-8	-21	-8	-19	-32	-61	-73	-70
Investing Cash Flow	-	-	-24	0	0	0	-148	-35	-173
Financing Cash Flow	11	6	43	130	-1	-1	234	133	218
Change in Cash	2	-2	-2	121	-20	-34	24	23	-25

Mutual Funds that own Enliven Therapeutics Stock

Check out the Mutual Funds with significant holdings in Enliven Therapeutics.

Funds	Holdings	Shares Held
Fidelity Securities Fund	2.900148%	2124961
VANGUARD INDEX FUNDS	2.884842%	2113746
Fidelity Select Portfolios	2.242732%	1643267
Fidelity Advisor Series VII	1.240415%	908862
Fidelity Capital Trust	0.891339%	653091

See all

Global Institutional Holdings in Enliven Therapeutics

Funds	Holdings
Vanguard	4.1%
iShares	3.38%
Peter Harwin	2.53%
Stanley Druckenmiller	1.29%
Felix Baker	1.24%

See all

Enliven Therapeutics News & Key Events

Insights on Enliven Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Best in 3 Years
In the last 3 years, ELVN has outperformed top 5 stocks with highest market-cap in its industry
NO EFFECT
Against Peers
In the last 1 year, Moderna, Inc. Common Stock has given 482.5% return, outperforming this stock by 324.2%
NEGATIVE IMPACT
Price Dip
In the last 7 days, ELVN stock has moved down by -12.6%

About Enliven Therapeutics

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.

Organisation	Enliven Therapeutics
Headquarters	6200 Lookout Road, Boulder, CO, United States, 80301
Industry	Biotechnology
CEO	Mr. Richard A. Fair M.B.A.
E-voting on shares	Click here to vote

Key Management of Enliven Therapeutics

Name	Title
Mr. Richard A. Fair M.B.A.	CEO, President & Director
Mr. Samuel S. Kintz M.B.A.	Co-Founder & Head of Pipeline
Mr. Benjamin Hohl	CFO & Head of Corporate Development
Dr. Helen Louise Collins M.D.	Chief Medical Officer
Dr. Joseph P. Lyssikatos Ph.D.	Co-Founder & Research Fellow
Mr. Anish Patel Pharm.D.	Co-Founder & COO
Dr. Galya D. Blachman Esq., Ph.D.	Chief Legal Officer & Head of Business Development
Damiette Smit	Vice President of Clinical Development

FAQs

What is Enliven Therapeutics share price today?

Enliven Therapeutics share price today is $50.17 as on September 17, 2026 at 7:42 pm IST. Enliven Therapeutics share today touched a day high of $50.55 and a low of $49.32.

What is the 52 week high and 52 week low for Enliven Therapeutics share?

Enliven Therapeutics share touched a 52 week high of $62.32 on August 5, 2026 and a 52 week low of $14.79 on January 6, 2026. Enliven Therapeutics stock price today i.e. September 17, 2026 at 7:42 pm IST is trending at $50.17,which is 19.50% down from its 52 week high and 239.33% up from its 52 week low.

What is Enliven Therapeutics's market capitalisation today?

Enliven Therapeutics market capitalisation is $0.00T as on September 17, 2026 at 7:42 pm IST.

How to invest in Enliven Therapeutics Stock (ELVN) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Enliven Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Enliven Therapeutics Shares that will get you 0.0299 shares as per Enliven Therapeutics share price of $50.17 per share as on September 17, 2026 at 7:42 pm IST.

What is the minimum amount required to buy Enliven Therapeutics Stock (ELVN) from India?

Indian investors can start investing in Enliven Therapeutics (ELVN) shares with as little as ₹95.93 or $1 (as of September 17, 2026 at 7:43 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹959.30 in Enliven Therapeutics stock (as per the Rupee-Dollar exchange rate as on September 17, 2026 at 7:43 pm IST). Based on Enliven Therapeutics share’s latest price of $50.17 as on September 17, 2026 at 7:42 pm IST, you will get 0.1993 shares of Enliven Therapeutics. Learn more about fractional shares .